Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL8041708 | 0.96 | RIPK1 (0.37) | RIPK1ROCK1TPSAB1OPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL6489279 | 0.94 | RIPK1 (0.35) | RIPK1ROCK1TPSAB1OPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5629844 | 0.93 | OPRM1 (0.34) | RIPK1ROCK1TPSAB1OPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5211441 | 0.92 | RIPK1 (0.38) | RIPK1ROCK1TPSAB1OPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5208180 | 0.92 | RIPK1 (0.42) | RIPK1ROCK1F2ALDH1A1F10 | |
| Trifluoroacetic Acid SCHEMBL5212450 | 0.92 | RIPK1 (0.39) | RIPK1ROCK1TPSAB1OPRM1OPRD1 | |
| Trifluoroacetic Acid SCHEMBL5210860 | 0.91 | RIPK1 (0.42) | RIPK1ROCK1F2ALDH1A1F10 | |
| Trifluoroacetic Acid SCHEMBL5210720 | 0.90 | HSD17B3 (0.38) | RIPK1TPSAB1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5213696 | 0.90 | ROCK1 (0.39) | RIPK1ROCK1OPRM1OPRD1F2 | |
| Trifluoroacetic Acid SCHEMBL5210137 | 0.90 | RIPK1 (0.37) | RIPK1ROCK1TPSAB1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240154-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2007-02-28 | — | — | EP | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | RIPK1 1724/4885ROCK1 1847/4885TPSAB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.